IPO: Similar to 2024, the IPO market is expected to be lively in 2025 too. We mention this as numerous major companies are launching IPOs. SEBI has approved the IPOs of certain companies, whereas others are still awaiting approval. One of the firms anticipating IPO authorization is Anthem Biosciences. This firm linked to the pharmaceutical industry has submitted an application to SEBI for an IPO worth Rs 3395 crore. Anthem Biosciences will not create additional shares in its IPO. In this, promoters Ganesh Sambasivam and K Ravindra Chandrappa aim to divest their shares via Offer for Sale. Kindly be aware that the shareholders selling their shares will receive the proceeds from the IPO, while the company will not obtain any funds from the offering.
Shareholders selling their shares are…
Ganesh Sambasivam and K Ravindra Chandrappa aim to sell shares valued at Rs 350 crore each. Investor Viridity Tone LLP intends to gather Rs 1325 crore. Portsmouth Technologies LLC aims to sell shares valued at Rs 320 crore. Other shareholders selling their shares are Malay J Barua, Rupesh N Kinekar, Satish Sharma, Prakash Kariabettan, and K Ramakrishnan. The IPO’s lead managers include JM Financial, Citi, JP Morgan, and Nomura. Simultaneously, KFintech serves as the registrar for the public offering.
This firm will compete against companies such as Syngene International
The pharma firm located in Bengaluru is led by Ajay Bhardwaj, a former executive from Biocon, who serves as the founder, CEO, and managing director of Anthem Biosciences. The corporation was established in 2006. In the stock market, this firm will compete against companies such as Syngene International, Divi’s Laboratories, and Sai Life Sciences.
Disclaimer : For any financial invest anywhere on your own responsibility, Times Bull will not be responsible for it.